Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) Research & Development (2019 - 2025)

Viemed Healthcare's Research & Development history spans 7 years, with the latest figure at $598000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 25.53% year-over-year to $598000.0; the TTM value through Dec 2025 reached $3.0 million, down 1.66%, while the annual FY2025 figure was $3.0 million, 1.66% down from the prior year.
  • Research & Development reached $598000.0 in Q4 2025 per VMD's latest filing, down from $775000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $847000.0 in Q2 2025 to a low of $339000.0 in Q1 2021.
  • Average Research & Development over 5 years is $683650.0, with a median of $697000.0 recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 137.04% in 2021, then dropped 25.53% in 2025.
  • A 5-year view of Research & Development shows it stood at $612000.0 in 2021, then increased by 17.97% to $722000.0 in 2022, then decreased by 9.83% to $651000.0 in 2023, then increased by 23.35% to $803000.0 in 2024, then decreased by 25.53% to $598000.0 in 2025.
  • Per Business Quant, the three most recent readings for VMD's Research & Development are $598000.0 (Q4 2025), $775000.0 (Q3 2025), and $847000.0 (Q2 2025).